Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.64 |
| ▸ | PDE4A | P27815 | 3/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | HBB | P68871 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7296127 | 0.98 | ADORA2B (0.62) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL9260345 | 0.82 | ADORA2B (0.51) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL17311158 | 0.79 | ADORA2B (0.60) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL28516221 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| 1-Methylxanthine SCHEMBL10996 | 0.78 | ADORA2B (1.00) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL9574927 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL9949244 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL28648091 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL2837684 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL618977 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 501 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119817601-A | Composite microbial agent and application thereof in improving saline-alkali stress resistance of crops | 山东农大肥业科技股份有限公司 | 2025-04-15 | — | — | CN | claimed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | claimed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | claimed |
| EP-3900712-A1 | GPCR HETEROMER INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2021-10-27 | — | — | EP | claimed |
| EP-3727371-A1 | GPCR HETEROMER INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2020-10-28 | — | — | EP | claimed |
| US-20190209594-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2019-07-11 | — | — | US | claimed |
| EP-3452092-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-13 | — | — | EP | claimed |
| WO-2017191300-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-11-09 | — | — | WO | claimed |
| EP-2507241-A1 | METHANOCARBA ADENOSINE DERIVATIVES AND DENDRIMER CONJUGATES THEREOF | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2012-10-10 | — | — | EP | claimed |
| US-20110189255-A1 | DRUG-ELUTING STENTS FOR ADENOSINE RECEPTOR MODULATION | PURDUE RESEARCH FOUNDATION | 2011-08-04 | — | — | US | claimed |
| WO-1998057651-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | DISCOVERY THERAPEUTICS, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| EP-0814810-A1 | ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1998-01-07 | — | — | EP | claimed |
| US-5629298-A | INCREASING CONTRACTILE PERFORMANCE, ADENOSINE TRANSPORT INHIBITORS USED AS POTENTIATORS | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1997-05-13 | — | — | US | claimed |
| EP-0755254-A1 | PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION AND ENDOTOXIN-RELATED INJURY USING ADENOSINE AND PURINO RECEPTOR ANTAGONISTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1997-01-29 | — | — | EP | claimed |
| WO-1996028163-A1 | ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1996-09-19 | — | — | WO | claimed |
| CN-1031641-C | Process for preparing 8-substituted xanthine | BEECHAM WUELFING GMBH & CO KG (DE) | 1996-04-24 | — | — | CN | claimed |
| CN-1114880-A | Novel treatment | SMITHKLINE BEECHAM PLC (GB) | 1996-01-17 | — | — | CN | claimed |
| US-5461059-A | Antihistamine; treats allergies and asthma | LABORATOIRE THERAMEX S.A. (FR) | 1995-10-24 | — | — | US | claimed |
| WO-1995026728-A1 | PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION AND ENDOTOXIN-RELATED INJURY USING ADENOSINE AND PURINO RECEPTOR ANTAGONISTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1995-10-12 | — | — | WO | claimed |
| CN-1047502-A | The preparation method of 8-substituted xanthine | BEECHAM WUELFING GMBH & CO KG (DE) | 1990-12-05 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | ADORA2B 2902/4885ADORA2A 1801/4885PDE4A 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.